Ryan Jones - May 28, 2024 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
Chief Financial Officer
Signature
By: /s/ Ryan Jones
Stock symbol
KYTX
Transactions as of
May 28, 2024
Transactions value $
$13,152
Form type
4
Date filed
5/29/2024, 04:33 PM
Previous filing
Feb 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYTX Common Stock Options Exercise $7.94K +10.9K +41.91% $0.73* 36.8K May 28, 2024 Direct F1
transaction KYTX Common Stock Options Exercise $5.22K +7.15K +19.42% $0.73* 44K May 28, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYTX Stock Option (Right to Buy) Options Exercise $0 -10.9K -100% $0.00* 0 May 28, 2024 Common Stock 10.9K $0.73 Direct F1
transaction KYTX Stock Option (Right to Buy) Options Exercise $0 -7.15K -76.53% $0.00 2.19K May 28, 2024 Common Stock 7.15K $0.73 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the original number of shares subject to the option vested on April 15, 2021, and 1/48th of the original number of shares subject to the option vested in monthly installments thereafter.
F2 25% of the original number of shares subject to the option vested on January 1, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.